<DOC>
	<DOCNO>NCT00289809</DOCNO>
	<brief_summary>The purpose study determine maximum tolerate dose TLC D-99 combine ifosfamide efficacy combination term overall response rate , time progression time response</brief_summary>
	<brief_title>TLC D-99 Ifosfamide Metastatic Soft Tissue Sarcoma Patients</brief_title>
	<detailed_description>The Maximum Tolerated Dose combination determine Phase I terminate . Then , Phase II study start .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>Histologic diagnosis soft tissue sarcoma metastatic recurrent 6 month last chemotherapy Age &gt; /=18 yr PS &lt; /=2 Disease detectable almost 1 dimension Life expectancy &gt; /=3 mos Minimum 4 wks last radiotherapy Adequate medullary , liver , renal function Normal LVEF Written Informed Consent Pregnant breastfeed patient Serious concomitant disease control infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2009</verification_date>
</DOC>